Loading...
•
Sep 30, 2021
CryoPort Q3 2021 Earnings Report
Cryoport delivered record third quarter revenue driven by all areas of its business.
Key Takeaways
Cryoport reported a record third-quarter revenue of $56.7 million, driven by 38% organic growth year-over-year from Cryoport Systems and CRYOGENE, and strong revenue performance by MVE Biological Solutions and CRYOPDP. The company supports a record 582 clinical trials and eight commercial therapies in regenerative medicine.
Total revenue grew to a record $56.7 million.
Biopharma/Pharma revenue increased 371% year over year, or 41% organically.
Supported a record 582 clinical trials.
Expanded into 33 facilities in 16 countries and initiated further expansion in APAC and EMEA regions.
Forward Guidance
Cryoport anticipates up to another four (4) BLA and MAA submissions for Cryoport-supported products during the remainder of 2021 and, at this time, an additional twenty-one (21) filings in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...